---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-208688"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2024-08-28T23:59:59+00:00"
generated_at: "2026-05-31T07:07:45.002476+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Jazz Pharma wins partial injunction against Avadel's Lumryz, ongoing royalty above 3.5%

## Summary
- On August 27, 2024, U.S. District Court granted Jazz's motion for permanent injunction against Avadel.
- Injunction prevents Avadel from seeking FDA approval or marketing Lumryz for idiopathic hypersomnia or other new indications.
- Avadel is enjoined from infringing Claim 24 of Jazz's '782 patent through February 2036, except for narcolepsy and existing patients.
- Court awarded Jazz an ongoing royalty for future narcolepsy Lumryz sales at a rate to be determined above 3.5%.
- Jazz previously won jury verdict finding '782 patent valid and damages for past Lumryz sales.

## SEC filing metadata
- accession: 0001193125-24-208688
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2024-08-28T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000119312524208688/0001193125-24-208688-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000119312524208688/d886606d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-208688
- JSON: https://secwatch.observer/filing/0001193125-24-208688.json
- Plain text: https://secwatch.observer/filing/0001193125-24-208688.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.